I am running a special discount at DrugPatentWatch through the end of November:
50% off the Global and Individual Country Drug Patent Inventor Reports through November 30th 2011.
These Pharmaceutical Industry Reports are produced by data-mining the DrugPatentWatch Database, and provide detailed information on FDA-approved pharmaceutical drugs.
Please contact us with any special data needs beyond the existing report catalog.
| ||Global Drug Patent Inventor Report|
The Global Drug Patent Inventor Report profiles the individuals, countries, and US states leading pharmaceutical innovation.
$5,000 $2,500 until November 30th
| || Individual Country Drug Patent Inventor Report|
These Individual Country Drug Patent Inventor Reports profile the individuals leading pharmaceutical innovation in 20 countries, including Australia, Belgium, Canada, China, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, United Kingdom, and United States.
$195 – $795 $97.50 – $397.50 until November 30th
See other reports at the DrugPatentWatch Reports page.
The Association of University Technology Managers (AUTM) 2012 Venture Pitch Competition is calling for finalists to present to a venture capital judging panel at the AUTM Annual Meeting (which will be held in Anaheim from March 14-17, 2012).
The competition is open to all disciplines this year. So whether your company is considered life science, software, engineering-focused or even a game-based technology, all are welcome to submit.
Final presenters will all receive a $1,000 travel stipend and free registration to the AUTM Annual Meeting. The winner will still receive a $10,000 prize.
The deadline for submission is Monday, November 21, 2011. You can apply here: http://autmventure2012.istart.org/.
Drug Patent Expirations in November 2011
*Drugs may be covered by multiple patents
|Tradename||Applicant||Generic Name||Patent Number||Patent Expiration|
|APHTHASOL||Uluru||amlexanox||5,362,737||Nov 8, 2011|
|MAGNEVIST||Bayer Hlthcare||gadopentetate dimeglumine||5,362,475||Nov 8, 2011|
|ABLAVAR||Lantheus Medcl||gadofosveset trisodium||5,362,475||Nov 8, 2011|
|OMNISCAN||Ge Healthcare||gadodiamide||5,362,475||Nov 8, 2011|
|SYMBICORT||Astrazeneca||budesonide; formoterol fumarate dihydrate||5,349,945||Nov 12, 2011|
|CARDIZEM CD||Valeant Intl||diltiazem hydrochloride||5,364,620||Nov 14, 2011|
|VFEND||Pfizer||voriconazole||5,364,938||Nov 15, 2011|
|VISIPAQUE 270||Ge Healthcare||iodixanol||5,366,722||Nov 22, 2011|
|CHLORAPREP ONE-STEP FREPP||Carefusion||chlorhexidine gluconate; isopropyl alcohol||D386849||Nov 25, 2011|
|BAYCOL||Bayer Pharms||cerivastatin sodium||5,177,080||Nov 26, 2011|
|TESLASCAN||Ge Healthcare||mangafodipir trisodium||4,933,456||Nov 27, 2011|
|ZOLINZA||Merck||vorinostat||RE38506||Nov 29, 2011|
This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin.
Courtesy of DrugPatentWatch.com
The mission of the Food and Drug Administration (FDA) is to promote public health by ensuring the safety and quality of food and medical products sold in the United States. At this year's annual Biotechnology Industry Organization (BIO) convention, significant discussion revolved around the appropriate interpretation and execution of that mission.
The BIO meeting hosted 15 646 participants from across industry, government and the nonprofit sector, focusing on the current state of the biotechnology industry, as well as its challenges in seeking to further improve public welfare. Perhaps partly because this year's meeting was held in Washington, DC – the seat of the federal government and of BIO's headquarters – much attention was paid to the US regulatory environment. In particular, attendees debated the quandary faced every day by the FDA: how to enable access to novel therapies quickly, but only once their safety has been certified. Full details at the Journal of Commercial Biotechnology
As a result of the global recession that began in 2008, life sciences companies face a groundswell of new business and regulatory pressures that includes health care and patent reform, increased pricing pressures, and diluted markets. Bringing new products from discovery to market is becoming more expensive and unpredictable. In the pharmaceutical sector, some predict that the age of the blockbuster drug has ended as generics present a growing threat to the pharmaceutical giants. Further, with a large number of key patent expirations looming through 2014, analysts expect that large pharmaceutical companies will lose over US$150 billion of revenues of brand name drugs.
In response to declining sales and rising R&D costs, the life sciences industry is pursuing new market opportunities by expanding beyond the developed markets of the United States, Europe and Japan, and into emerging markets such as China and India. Despite market uncertainties, however, venture capital funding in the life sciences sector (including pharmaceuticals and medical devices) is on the rise with $2.1 billion going into 206 deals during the second quarter of 201l, an increase of 37 per cent in dollars and 12 per cent in deal volume. To survive – and thrive – in these tumultuous times, both large and small life sciences companies face pressure to develop new products and technological advancements.
Patents are pivotal to the life sciences industry. In order to succeed, life sciences companies must distinguish themselves from their competitors through their intellectual property portfolios. A successful patent portfolio represents a well-reasoned business strategy, where each patent is a single strategic building block in a larger portfolio that reflects present and future business objectives. A strong patent portfolio is also important in the current life sciences investment climate, where venture capital funding is often dependent on whether a company has secured its intellectual property assets, thereby validating a company's technology and demonstrating its commercial potential. Although building and maintaining a strong patent portfolio is important for all life sciences companies, it is most critical for early-stage companies. Patent portfolios are often the driving force for major events in the life cycle of a life sciences company, including mergers and acquisitions, public offerings, venture capital investment, strategic collaborations, joint ventures and litigation.
As a result of recent measures taken by the US Congress, the US Patent and Trademark Office (USPTO) and the US Supreme Court to reform the current US patent system, life sciences companies must respond with strong patent strategies that address these reforms without sacrificing the company's competitive edge in the marketplace. Such comprehensive technology strategies must maximize patent coverage of a company's current core technology and future improvements, monitor the patent landscape and explore ways to patent white space, and consider cross-licensing opportunities with competitors. With these strategies in place, life sciences companies can withstand patent reform and ensure their success in today's competitive and rapidly evolving global commercialization landscape. Full details at the Journal of Commercial Biotechnology
There are various definitions of an entrepreneurial university, yet there is a lack of agreement about its core components. This article defines the five key characteristics of an entrepreneurial university based on examples of successful bio-clusters in the United States and Europe, and suggests an agenda for stakeholders. Full details at the Journal of Commercial Biotechnology
Canada's biotech sector ranks within the top five globally, but its life sciences venture capital (VC) industry is among the worlds weakest. This makes for an interesting case study in understanding the disconnect between low levels of VC and a healthy innovation ecosystem in terms of R&D spending, skilled workforce and enterprise support. Three key provinces (Quebec, Ontario and British Columbia) that have taken significantly different approaches to attracting VC are large enough to attract as much government investment as whole emerging markets. The aim of this article is to present evidence from a Canadian natural economic experiment in order to evaluate the effectiveness of varying government policies in attracting VC investment, to illustrate how these policies need tailoring to individual sub-sectors of the life sciences sector, and to highlight potential policy mechanisms that may be applicable beyond Canada's borders. We employ VC returns on investment (ROI) and exit data as a proxy for our evaluation. Our results suggest that government biotechnology investment needs to be structured end-to-end from early to late stage in order to be successful, that prevalence of private and international VC flows is critical for generating market efficiency, and that there is an ‘optimal’ efficient amount of capital before ROI result in diminishing returns. Full details at the Journal of Commercial Biotechnology
This article, written from an industry perspective, examines the current trend towards the implementation of single-use disposable technologies in the biopharmaceutical and biotechnology sectors. Single-use technologies are generally sterile, plastic disposable items implemented to replace traditional pharmaceutical processing items that require recycling, cleaning and in-house sterilisation. The forces driving the technological change are a mix of process efficiencies (including cost reduction) and sterility assurance. This article examines the advantages of some single-use systems used for aseptic processing, although in doing so a cautionary approach is adopted, particularly with regard to the validation requirements and practical considerations when such technologies are implemented. Full details at the Journal of Commercial Biotechnology